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Abstract: Lymphedema affects up to 50% of all breast cancer survivors. 
Management with pneumatic compression devices (PCDs) is controversial, 
owing to the lack of methods to directly assess benefit. This pilot study 
employed  an  investigational,  near-infrared  (NIR)  fluorescence  imaging 
technique to evaluate lymphatic response to PCD therapy in normal control 
and  breast  cancer-related  lymphedema  (BCRL)  subjects.  Lymphatic 
propulsion rate, apparent lymph velocity, and lymphatic vessel recruitment 
were measured before, during, and after advanced PCD therapy. Lymphatic 
function  improved  in  all  control  subjects  and  all  asymptomatic  arms  of 
BCRL  subjects.  Lymphatic  function  improved  in  4  of  6  BCRL  affected 
arms,  improvement  defined  as  proximal  movement  of  dye  after  therapy. 
NIR  fluorescence  lymphatic  imaging  may  be  useful  to  directly  evaluate 
lymphatic  response  to  therapy.  These  results  suggest  that  PCDs  can 
stimulate lymphatic function and may be an effective method to manage 
BCRL, warranting future clinical trials. 
© 2010 Optical Society of America 
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1. Introduction 
In the U.S., the overall rate of cancer survivorship has steadily increased, with cancer stage at 
time of diagnosis remaining the primary prognostic indicator of five-year survival rate [1]. 
Despite playing a critical role for defining the most efficacious treatment, nodal staging can 
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treatment consequence whose risk is further exacerbated by radiation treatment [2–4]. BCRL 
incidence rates range between 3 to 15% after sentinel lymph node biopsy; 10 to 20% after 
complete  axillary  dissection  without  subsequent  radiation;  and  30  to  50%  after  complete 
axillary  dissection  followed  by  radiotherapy  [4–7].  Arm  lymphedema  symptoms  include 
decreased range of motion and function, pain, frustration, anger, and depression [8]. If left 
untreated  or  if  treated  ineffectively,  lymphedema  can  progress  to  extreme  disfigurement, 
chronic infection, and lymphangiosarcoma. 
Standard  management  of  lymphedema  (including  BCRL)  is  the  use  of  complete 
decongestive therapy (CDT), which includes manual lymphatic drainage (MLD), compression 
bandaging, therapeutic exercise, and skin care [9]. Therapeutic efficacy is typically assessed 
over several weeks by measuring the change in arm volume as indicated by circumferential 
arm  measurements or  water  displacement. Depending  upon the criteria  used to determine 
response, 50% to greater than 80% of arm lymphedema patients maintain benefits obtained 
from professionally-administered CDT over a period of 12 months [10–13]. Lack of patient 
compliance  with  prescribed  self-MLD  therapy  is  a  major  cause  of  treatment  failure  [14]. 
When used as part of home management, pneumatic compression devices (PCDs) have been 
proposed as a replacement for or adjunctive to self-MLD treatment. PCDs typically consist of 
sleeve garments comprised of chambers that, when sequentially inflated and deflated along 
the length of the arm, are designed to push lymph and extravascular fluids proximally towards 
the axilla or other  functional draining basins  within the trunk [15]. Less advanced PCDs 
consist of simple compressors with a single outflow port to a non-segmented sleeve (HCPC 
procedure code, E0650) or a segmented sleeve without manual control of pressure in each 
chamber  (procedure  code,  E0651).  While  Medicare  states  that  either  an  E0650  or  E0651 
device  is  sufficient  to  meet  the  clinical  needs  of  a  patient  in  whom  MLD  is  insufficient 
[16,17],  clinical  practice  suggests  that  an  advanced,  programmable  PCD  consisting  of  a 
segmented sleeve with a calibrated, gradient compressor (procedure code, E0652) provides 
greater efficacy. Unfortunately, payment for code E0652 is not typically made unless there is 
documentation that (i) an E0650 or E0651 device has been tried and found insufficient and 
that (ii) there is “clinical response” to the initial treatment with the E0652 device. Yet there is 
no method to directly evaluate the response of lymphatic function to an initial treatment. 
A  method  to  evaluate  lymphatic  function  prior  to  and  immediately  following  therapy 
could  result  in  (i)  choosing  the  most  efficacious  treatment  approaches  based  upon  direct 
evidence of improved lymphatic function, (ii) improved patient compliance, and (iii) efficient 
evaluation of new treatments. The objective of this pilot study was to use an investigational 
imaging technique of near-infrared (NIR) fluorescence imaging [18,19] to evaluate response 
of the lymphatic function to advanced PCD therapy in normal control subjects and in persons 
with BCRL. 
2. Methods 
Nine subjects were enrolled, 3 normal control subjects and 6 women diagnosed with unilateral 
BCRL,  under  a  combination,  Phase  0  IND  #:  102,765;  Table  1  summarizes  the  subject 
demographics. After informed consent was obtained, the subjects received NIR-fluorescent 
contrast injections, and were imaged for approximately 2.5 hours, during which time PCD 
treatment occurred (schematic of timeline shown in Fig. 1). Vital signs were monitored during 
imaging and a follow up phone call was made 24 hours after injections began to monitor 
adverse events. No adverse events occurred. 
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Subject 
ID  Sex  Age  PCD 
Arm  BCRL 
Months 
post 
diagnosis 
Stage at 
diagnosis 
Surgical 
intervention*  Nodes removed* 
BCRL 1  F  51  L  Y  13  I  Mastectomy  Biopsy 
BCRL 2  F  58  L  Y  16  I  Lumpectomy  Lymphectomy 
BCRL 3  F  51  R  Y  7  II  Mastectomy   
BCRL 4  F  57  R  Y  63  II  Mastectomy 
plus Radiation   
CTL 1  F  50  R  N  N/A       
BCRL 5  F  65  L  Y  26  I  Mastectomy   
CTL 2  M  24  R  N  N/A       
BCRL 6  F  58  R  Y  56  II  Mastectomy   
CTL 3  F  54  L  N  N/A       
* indicates as reported by the subject 
 
 
Fig. 1. Timeline for subjects participating in study. 
For  fluorescent  contrast,  subjects  received  up  to  6  intradermal  injections  of  25  µg  of 
Indocyanine Green, USP, (ICG, PULSION Medical Systems AG, Munich, Germany), diluted 
in 100 µL of saline in each arm. Injection sites were located on the lateral hand (two), on the 
medial wrist (up to two), and over the lateral and medial antibrachial muscles (up to two). 
Two custom-built, NIR optical imaging systems were used simultaneously and independently 
to  image  both  arms  of  the  subject. The  imaging  systems  have  been  described  previously 
[20,21] but briefly consist of: (i) a 785 nm NIR laser diode, illuminating tissues at fluencies of 
<1.9  mW/cm
2  over  as  great  as  900  cm
2  area  and  (ii)  a  NIR-sensitive  intensified  charge 
coupled device (ICCD) camera outfitted with holographic and bandpass filters to efficiently 
collect fluorescent light at 830 nm, Fig. 2 presents a schematic of the imaging system. All 
subjects were placed in a supine position and, immediately following agent administration, 
were  imaged  for  approximately  one  hour  to  determine  the  baseline  lymphatic  flow  and 
Informed Consent 
Imaging Session 
2.5 hrs 
Pre 
1 hr 
Follow Up Phone 
Call at 24 hrs 
PCD 
1 hr 
Post 
30 mins 
Imaging  Imaging  PCD  Treated Arm 
Imaging  Imaging  Imaging  Untreated Arm 
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imaging  system  was  used  to  image  the  contralateral,  untreated  arm  to  determine  if  the 
treatment  caused  a  systemic  effect  on  the  lymphatic  system.  Because  the  PCD  garment 
prevented incident excitation of tissue surfaces, no imaging was performed on the treated arm 
during treatment. After PCD treatment, both imaging systems were again used to determine 
the effects of PCD treatment on the treated and untreated arms. 
 
 
Fig. 2. Schematic of the imaging system, which includes (i) a diffused 785 nm NIR laser with a 
laser clean up filter, (ii) a NIR-sensitive ICCD camera, (iii) holographic and bandpass filters to 
efficiently collect fluorescent light at 830 nm, and (iv) a computer to control the system and 
collect the images. 
PCD treatment was applied by the Flexitouch® system (Tactile Systems Technology, Inc., 
Minneapolis, MN), an automated, calibrated, and programmable PCD specifically designed to 
treat lymphedema [21,22]. The garments were fitted specifically to each subject according to 
manufacturer instructions, and placed around the trunk, chest and arm. The PCD treatment 
began with 
• initial truncal decongestion lasting approximately 12 minutes during which a gradient 
pressure was applied to the trunk and chest areas in a preparative phase that emptied 
draining basins; and continued with 
•  initial  arm  preparation,  lasting  approximately  18  minutes,  during  which  a  gradient 
pressure was applied to the more proximal areas of the arm; and finally culminating 
with 
16-bit, frame 
transfer CCD 
GEN III 
intensifier 
intensifier 
DC bias 
laser 
DC bias 
lens & diffuser 
Tissue 
filters 
lens 
laser driver 
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cycles of mild variable pressure and release were applied sequentially to the limb and 
trunk in a distal-to-proximal manner. 
By initially clearing the adjacent quadrant(s), ipsilateral truncal quadrant, and more proximal 
areas  of  existing  or  normal  lymph  load,  the  advanced  PCD  used  mimics  MLD,  and 
presumably enables receiving lymphatic basins to more effectively receive and process the 
lymphatic load from the affected arm. 
Image analysis for apparent lymphatic velocity and rate of propulsion was performed as 
described previously [21]. Briefly, images were previewed in ImageJ (Version 1.43i, National 
Institutes of Health, Bethesda, MD) to identify subsets with notable lymphatic architecture 
and with lymphatic flow. Lymphatic transport is defined herein as a “packet” of ICG that 
travels along a lymphatic vessel. In the images where lymphatic transport was observed, a 
custom MATLAB (Version 7.6.0 R2008a, Mathworks, Natick, MA) program was used to 
identify lymphatic vessels and measure the fluctuation of fluorescent intensity across regions 
of interest over time in order to calculate the apparent velocity of each “packet” of ICG-laden 
lymph. Positive apparent velocities designate proximal flow, whereas negative values signify 
distal movement away from the axilla. Rates of lymphatic propulsion were determined by 
counting the number of propelled “packets” over a period of time. Data of apparent lymph 
velocity and propulsion rate were grouped into pre-, during, and post-PCD treatment for both 
treated and untreated arms. 
3. Results 
Results from the control subjects are summarized in Figs. 3 and 7C. In every control subject, 
the rate of lymphatic propulsion increased during and post-treatment as compared to pre-
treatment, as shown in Fig. 3A. There was no statistical difference in the mean velocities pre-, 
during, or post-treatment, as shown in Fig. 3B. Negative velocities (or distal movement of 
“packets”)  were  observed  before  and  during  treatment,  but  none  were  observed  after 
treatment. Figure 4 displays pre- (4A, Media 1) and post- (4B, Media 2) treatment movies 
from one control subject, CTL 3, showing improvement in rate of lymph propulsion as well 
vessel  recruitment.  Pre-treatment,  only  one  lymphatic  vessel  clearly  delineated  with  ICG 
(4A), while post-treatment, a second vessel is well defined (4B). Vessel recruitment was seen 
in  2  of  the  3  control  subjects.  Lymphatic  function  improved  in  all  control  subjects,  as 
indicated through increased rates of lymphatic propulsion and/or vessel recruitment. Figure 7 
C displays the statistically significant difference between the rates of propulsion in the treated 
arms pre- and post-treatment (p < 0.05). The rate of propulsion tended to increase in the 
untreated arms of control subjects, not only after PCD treatment, but also during the initial 
preparation  phases,  suggesting  improved  systemic  lymphatic  drainage  associated  with 
advanced PCD (see Fig. 9). 
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Fig. 3. Comparison of rate of lymph propulsion (A) and velocity (B) in untreated and treated 
arms of normal control subjects. 
 
Fig. 4. The upper arm and axilla of Control Subject 3 before PCD treatment (A, Media 1) and 
after PCD treatment (B, Media 2). After treatment, recruitment of vessels and increased rate of 
propulsion are observed. 
In the affected arm of the lymphedema subjects rate of propulsion and velocity analyses 
were not possible due to the abnormal lymphatic architecture and obscuration of functional 
lymph vessels by diffuse and dense ICG-laden dermal lymph vessels within the arm. Proximal 
advancement of ICG towards the axilla or shoulder was nonetheless observed after treatment 
in the affected arms of 4 of 6 BCRL subjects and was considered evidence of fluid drainage 
and stimulation of lymphatic function. Figure 5 presents pre- (A, B, C) and post- (D, E, F) 
treatment  images  from  three  BCRL  subjects.  Before  treatment,  ICG  was  present  in  two 
subjects up to the elbow (5A and 5B); after treatment, the ICG travelled proximally above the 
elbow into the upper arm (5D and 5E). The proximal movement is highlighted by a white 
circle denoting the same injection site (5B and 5E) seen in each image. In the third subject, 
prior to treatment, the ICG fluorescence was only present at the injection site (5C), while after 
PCD treatment, the ICG had moved proximally throughout the entire arm (5F). In 2 of the 6 
lymphedema subjects, the proximal movement of ICG continued into the axilla and shoulder, 
as shown in Fig. 6 (post-treatment proximal movement into the axilla (6B) and shoulder and 
back (6C) as compared with pre-treatment (6A)). Pre-treatment, ICG fluorescence was not 
detected in the shoulder or lateral upper arm of any subjects in the study. 
A 
CTL 3 
Control Arm 
Pre 
B 
CTL 3 
Control Arm 
Post 
Axilla 
Elbow 
Axilla 
cm 
Elbow 
cm 
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Fig.  5.  Advancement  of  ICG  in  the  affected  arms  of  3  lymphedema  subjects  after  PCD 
treatment. In two subjects, BCRL 4 and 5, ICG is not present above the elbow pre-treatment (A 
and B, respectively), whereas the ICG has advanced past the elbow and into the upper arm 
post-treatment (D and E).  In another subject, BCRL 6, prior to treatment (C), the  ICG is 
present  only  at  the  injection  site,  and  after  treatment  (F),  the  ICG  has  spread  proximally 
through the arm. 
 
Fig. 6. Pre- (A) and post- (B and C) PCD treatment images of affected arm of lymphedema 
subject, BCRL 4. Lymphatic fluid moved towards the axilla (B) and into the shoulder (C) after 
PCD treatment, as compared with pre-PCD treatment (A). 
Results from the asymptomatic arms of the BCRL subjects are summarized in Fig. 7. In 
every BCRL  untreated arm,  the rates of lymphatic propulsion increased post-treatment as 
compared  to  pre-treatment  and  in  4  of  6  arms,  the  rates  increased  during  treatment  as 
compared to pre-treatment (Fig. 7A). There was no statistical difference in the mean velocities 
pre-, during, or post-treatment in the BCRL subjects, as seen in Fig. 7 B. As seen in the 
control subjects, negative velocities were observed in asymptomatic arms before and during 
treatment, none were observed after treatment. Figure 7C displays the statistically significant 
difference between the propulsive rates measured, pre- and post-treatment as well as during 
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(C) 2010 OSA 2 August 2010 / Vol. 1,  No. 1 / BIOMEDICAL OPTICS EXPRESS  121treatment and post-treatment (p < 0.05). This statistical difference is especially notable since 
there was not a significant difference in the control, untreated arms. Figure 8 displays the top 
of the hand and wrist of one BCRL subject, BCRL 1, pre- (8A, Media 3), during (8B, Media 
4), and post- (8C, Media 5) PCD treatment. The videos show increased rate of propulsion 
during (8B) and after (8C) treatment as compared to before treatment (8A). Unlike in the 
control subjects, in the untreated arms of the BCRL subjects, there was a significant increase 
in the rates of propulsion (p < 0.05) during the initial preparation phases and the arm drainage 
phase of treatment (Fig. 9). This may suggest a systemic compensation mechanism in BCRL 
subjects  in  response  to  preparatory  phases  of  the  PCD  treatment.  Such  a  compensation 
mechanism  may  not  be  needed  in  normal,  healthy  subjects  with  functioning  lymphatics. 
Lymphatic function improved in all BCRL subjects, as indicated through increased frequency 
of lymph propulsion in the untreated, asymptomatic arms and proximal movement of ICG in 
the treated, symptomatic arms. 
 
Fig. 7. Comparison of lymph propulsion rate (A) and velocity (B) in asymptomatic arm of 
BCRL subjects and summary of all rate of propulsion results (C). 
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Fig. 8. The top of the hand and wrist of the asymptomatic arm of subject BCRL 1 pre- (A, 
Media 3), during (B, Media 4), and post- (C, Media 5) PCD treatment. The videos display an 
increased  rate  of  lymphatic  propulsion  during  (B,  Media  4)  and  after  (C,  Media  5)  PCD 
treatment when compared with before treatment (A, Media 3). 
 
Fig. 9. Rate of propulsion of “packets” in contralateral arm (1) pre massage, (2) during the 
trunk and arm preparation phase, (3) during the arm drainage phase, and (4) after the PCD 
treatment. 
4. Discussion 
The burden of BCRL management is eased with early detection [9,23,24], and adherence to 
treatment plans [14]. Symptomatic improvement has been demonstrated to varying degrees by 
different treatment options: CDT, microsurgery, PCDs and structured exercise [14,25–28]. 
Heretofore,  no  method  existed  to  directly  and  immediately  evaluate  improvement  in 
lymphatic function; therefore, there has been no mechanism by which to assess efficacy of 
clinical  intervention.  Using  the  same  approach  as  described  herein,  Tan,  et  al.,  recently 
demonstrated  the  first  case  of  real-time,  direct  measurement  of  lymphatic  function  in 
lymphedema  subjects  after  MLD  treatment  [28].  The  treatment  provided  by  some  PCD 
systems,  such  as  the  Flexitouch,  is  intended  to  replicate  the  magnitude,  timing,  and 
sequencing  pattern  of  the  gently  applied  pressures  of  MLD  [15],  allowing  lymphedema 
patients to receive MLD at home. Ridner, et al., (2008) found that after incorporating PCD 
into  home,  daily  lymphedema  care,  95%  of  patients  reported  limb  volume  reduction  or 
maintenance [26]. When compared to women with BCRL who used self-administered MLD, 
significantly greater limb volume reductions and weight loss occurred when using the same 
PCD system [29] studied herein with NIR fluorescence imaging. 
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treated and untreated arms of control subjects is an indication that PCD treatment systemically 
stimulated the lymphatic system. Unfortunately, the BCRL subjects imaged in this study had 
BCRL  diagnosed  7  –  63  months  prior  to  the  study,  which  may  have  contributed  to  the 
abundance  of  aberrant  lymphatic  architecture  in  their  symptomatic  arms  that  could  have 
obscured  the  imaging  of  deeper  functioning  vessels.  Another  explanation  may  be  the 
progressive loss of functioning lymphatic vessels within the affected limbs. In an earlier study 
(Rasmussen  et  al.  2009,  2010),  NIR  fluorescence  imaging  captured  aberrant  lymphatic 
function  in  a  woman  with  unilateral  BCRL  following  bilateral  mastectomies,  where  her 
asymptomatic  arm  displayed  regions  of  lymphatic  hyperplasia  connected  by  functioning 
dilated lymphatic vessels that displayed reflux or distal transport in addition to proximal flow 
[18,21]. 
Longitudinal  NIR  imaging  studies  are  needed  to  determine  whether  such  lymphatic 
abnormalities  are  present  prior  to  the  onset  of  symptoms  and  progress  with  time  to  the 
phenotypes presented  herein. An  understanding of the progression of BCRL is  needed to 
effectively employ evidence-based practices to prevent onset and better manage the disease. 
For example, Torres Lacomba, et al., demonstrated the effectiveness of prophylactic CDT in 
delaying the onset and possibly reducing incidence of BCRL [30]. The option of home-use of 
a PCD device could have significant implications as a prophylactic device for women who are 
not diagnosed with BCRL, but who are at risk for the disease. Until now there has been no 
diagnostic  technique  with  sufficient  spatial  and  temporal  resolution  to  directly  assess  or 
longitudinally image change in lymphatic function and architecture with progressive disease 
in order to justify the addition of prophylactic treatments. Given the variability of treatment 
response, a diagnostic technique to assess individual treatment efficacy could improve the 
efficacy of prescribed treatments and patient compliance, resulting in better management of 
the disease. In summary, the trends in this pilot study provide (i) evidence of the efficacy of 
advanced  PCDs  with  truncal  treatment,  (ii)  data  to  power  future  evidence-based  efficacy 
trials,  and  (iii)  justification  for  longitudinal  studies  to  better  deploy  existing  and  new 
treatments to better manage and possibly prevent BCRL. 
NIR fluorescence imaging offers unique advantages for imaging the lymphatic system. 
First of all, the technology involves microdosing of fluorophore, mitigating the potential for 
adverse events following repeated imaging and enabling quantification of dynamic lymphatic 
transport.  We  have  observed  that  the  dynamical  motion  for  quantification  of  lymphatic 
function seems to depend upon small doses of dye. At high doses of NIR dye, the lymphatic 
vessels appear to be saturated and stained, preventing observation of propulsive “packets” of 
lymph flowing through lymphatic vessels. While there have been a number of planar NIR 
imaging devices described in the literature (for review see Marshall, et al., 2010), lack of 
sensitivity prevent their use following microdose administration of dye [31]. The large mg 
amounts of dye may be responsible for the lack of dynamical lymph motion observed using 
these devices. Secondly, microdosing, defined by the FDA as 1/100th of a pharmacological 
dose of a labeled therapeutic agent, or less than 100 µg of a peptide- or 30 nanomoles of a 
protein- based imaging agent, efficiently allows for replacement of dim ICG with brighter, 
“first-in-human” NIR fluorophores. Previously, we have shown as little as 10 µg of ICG can 
be  detected  non-invasively  [20]  establishing  the  feasibility  for  detecting  microdosages  of 
brighter, “first-in-humans” NIR agents. Finally, since instrument response falls precipitously 
with time-dependent operation, NIR optical tomography in both time and frequency-spaces 
will likely require high sensitivity for clinical relevance [19]. By focusing upon improved 
sensitivity,  we  have  opened  up  opportunities  to  (i)  non-invasively  visualize  lymphatic 
function in humans; (ii) introduce “first-in-humans” NIR imaging agents, and (iii) conduct 
tomographic imaging with time-dependent approaches. 
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